A Two-Step Pretargeted Nanotherapy for CD20 Crosslinking May Achieve Superior Anti-Lymphoma Efficacy to Rituximab

Theranostics- Canada

doi 10.7150/thno.12040

Full Text

Abstract

Available in

Categories

Date

January 1, 2015

Authors

Jindřich Kopeček

Publisher

Ivyspring International Publisher

Related search

Efficacy of Rituximab (Anti-Cd20) for Refractory Systemic Lupus Erythematosus Involving the Central Nervous System

Annals of the Rheumatic Diseases

Molecular Biology

English

Two Structurally Different Rituximab-Specific CD20 Mimotope Peptides Reveal That Rituximab Recognizes Two Different CD20-Associated Epitopes

Journal of Immunology

English

B Cell Therapy for Rheumatoid Arthritis: The Rituximab (Anti-Cd20) Experience

Annals of the Rheumatic Diseases

Molecular Biology

English

Anti-Lymphoma Efficacy Comparison of Anti-Cd20 Monoclonal Antibody-Targeted and Non-Targeted Star-Shaped Polymer-Prodrug Conjugates

Organic Chemistry

Molecular Medicine

Analytical Chemistry

Theoretical Chemistry

Pharmaceutical Science

English

A Step Towards a New Targeted Nanotherapy for Pancreatic Cancer

Cancer Biology and Therapy

Cancer Research

Molecular Medicine

English

Regulation of CD20 in Rituximab-Resistant Cell Lines and B-Cell Non-Hodgkin Lymphoma

Clinical Cancer Research

Cancer Research

English

Characterization of Novel Murine Anti-Cd20 Monoclonal Antibodies and Their Comparison to 2B8 and C2B8 (Rituximab)

International Journal of Oncology

Cancer Research

English

Rituximab in CD20 Positive Multiple Myeloma

Cancer Research

English

Phase I Study of Chimeric Anti-Cd20 Monoclonal Antibody in Chinese Patients With CD20-positive Non-Hodgkin’s Lymphoma

Chinese Journal of Cancer Research

Cancer Research

English